The Colony-Stimulating Factor 3 Receptor (CSF3R), the receptor for granulocyte colony-stimulating factor (G-CSF), has expanded from a hematopoietic regulator to a multifunctional signalling molecule with significant relevance in gynaecological biology. …
Endometrioid borderline tumors (EBTs) and seromucinous borderline tumors (SMBTs) are rare ovarian neoplasms with distinct histologic features. However, the molecular profiles of EBTs and SMBTs remain incompletely characterized. We performed …
To evaluate the incidence of tubo-ovarian abscess (TOA) in patients with ovarian endometrioma (OE) undergoing infertility treatment and to describe treatment approaches and clinical outcomes, including transvaginal ultrasound-guided drainage.
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare (prevalence ~ 1:2 million), devastating genetic disorder characterized by progressive heterotopic ossification. Crucially, surgical trauma is a potent trigger for catastrophic new bone …
Endometriosis and polycystic ovary syndrome (PCOS) are common, multifactorial gynecological disorders shaped by endocrine imbalance, immune dysfunction, metabolic disruption, genetic susceptibility, and environmental exposures. Despite their major contribution to infertility …
Up to 1.6% of patients with endometriosis develop epithelial ovarian carcinoma. The genetic overlap between endometriosis and ovarian cancer has not been fully characterized. This review aims to describe the …
Background: Ovarian cystectomy is standard treatment for endometrioma but is associated with decreased ovarian reserve. Catheter-directed sclerotherapy (CDS) is an ovary-sparing image-guided alternative; however, supporting evidence comprises retrospective comparative and …
Mature cystic teratomas (MCTs) and endometriosis are the most common benign diseases in women of reproductive age. Their coexistence was traditionally considered rare. However, recent evidence suggests otherwise. This study …
Ovarian cancer was the eighth most frequently diagnosed cancer among women in 2022. The global age-standardized incidence rate of ovarian cancer decreased from 7.22/100,000 to 6.71/100,000 from 1990 to 2021. …
What is the current landscape of randomized controlled trials (RCTs) evaluating stem cell-based therapies for women's reproductive diseases, and how effectively has preclinical research informed their clinical translation?